Get the Stockscreener App
2.50
2.01%
0.0492
After Hours:
2.50
Mei Pharma Inc stock is traded at $2.50, with a volume of 114.88K.
It is up +2.01% in the last 24 hours and down -10.71% over the past month.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
See More
Previous Close:
$2.4508
Open:
$2.47
24h Volume:
114.88K
Relative Volume:
2.74
Market Cap:
$16.66M
Revenue:
$105.38M
Net Income/Loss:
$17.78M
P/E Ratio:
-0.54
EPS:
-4.63
Net Cash Flow:
$-50.48M
1W Performance:
-7.41%
1M Performance:
-10.71%
6M Performance:
-11.97%
1Y Performance:
-59.45%
1-Day Range:
$2.458
$2.50
1-Week Range:
$2.43
$2.68
52-Week Range:
$2.43
$6.3883
Mei Pharma Inc Stock (MEIP) Company Profile
Name
Mei Pharma Inc
Sector
Industry
Phone
858-369-7100
Address
11455 EL CAMINO REAL, SAN DIEGO, CA
Compare MEIP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MEIP
Mei Pharma Inc
|
2.50 | 16.66M | 105.38M | 17.78M | -50.48M | 2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mei Pharma Inc Stock (MEIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-24 | Downgrade | Laidlaw | Buy → Hold |
| Mar-25-22 | Downgrade | Jefferies | Buy → Hold |
| Mar-25-22 | Downgrade | Stifel | Buy → Hold |
| Mar-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-03-22 | Initiated | Jefferies | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-29-20 | Initiated | SunTrust | Buy |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Jul-27-18 | Upgrade | Stifel | Hold → Buy |
| Jul-13-18 | Initiated | SunTrust | Buy |
| Apr-18-16 | Reiterated | Wedbush | Neutral |
| Mar-23-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-18-14 | Reiterated | ROTH Capital | Buy |
| Oct-16-14 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Brean Capital | Buy |
| Oct-22-13 | Reiterated | Stifel | Buy |
| Apr-15-13 | Initiated | Stifel | Buy |
View All
Mei Pharma Inc Stock (MEIP) Latest News
MEI Pharma (NASDAQ:MEIP) Earns Buy Rating from Analysts at StockNews.com - Defense World
MEI Pharma stock hits 52-week low at $2.54 amid market challenges - Investing.com Australia
MEI Pharma stock hits 52-week low at $2.54 amid market challenges By Investing.com - Investing.com South Africa
MEI Pharma (LTS:0JW9) 5-Day RSI : 36.09 (As of Dec. 05, 2024) - GuruFocus.com
MEIP (MEI Pharma) Financial Strength : 7 (As of Sep. 2024) - GuruFocus.com
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
MEI Pharma (LTS:0JW9) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
MEI Pharma Reports Strategic Shift Amid Financial Losses - TipRanks
MEI Pharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com
MEI Pharma reports Q1 EPS ($1.20) vs. $8.46 last year - TipRanks
MEI Pharma Explores Strategic Sale Amid Cash Preservation Efforts, Reports $26.9M Cash Position | MEIP Stock News - StockTitan
Acute Myeloid Leukemia (AML) Treatment Market in APAC to Grow by USD 305.8 Million from 2024-2028, Driven by High Incidence and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
Aardvark Therapeutics, Inc. agreed to acquire rights, title and interest in and to certain assets related to ME-344 from MEI Pharma, Inc. for $62.5 million. - Marketscreener.com
Data Readouts At EHA Congress 2021 (APTO, XFOR, GBT, CRIS…) - RTTNews
Stocks to Watch: MEI Pharma, Hawaiian Electric Industries - MarketWatch
MEI Shares Rise After Entering Asset Purchase Agreement Valued at Up to $62 Million - MarketWatch
MEI Pharma postpones special meeting to vote on Infinity deal until July 23 - MSN
MEIP (MEI Pharma) Free Cash Flow per Share : $-7.57 (TTM As of Jun. 2024) - GuruFocus.com
Post Polycythemia Vera Myelofibrosis Market: Holistic - openPR
Ampio Pharmaceuticals (NYSE:AMPE) Coverage Initiated by Analysts at StockNews.com - Defense World
MEI Pharma stock hits 52-week low at $2.72 amid market challenges - Investing.com India
MEI Pharma stock hits 52-week low at $2.72 amid market challenges By Investing.com - Investing.com South Africa
Acute Myeloid Leukemia Market Trends, Key Drivers, Opportunities, Leading Players And Forecast To 2033 - WhaTech
Histone Deacetylase 2 Industry Forecast (2024-2034) Under Inflation - Apiculture Market: Report ...
Myelodysplastic Syndrome Drugs Market Research Explores Size, Market Competitive Landscape, Business Growth... - WhaTech
Chronic Lymphocytic Leukemia Treatment Market Advancements Highlighted by Comprehensive Analysis, Advanceme... - WhaTech
Follicular Lymphoma Treatment Market Insights Discussed Regarding Size, Trends, and Overview Report 2024-2033 - WhaTech
MEI Pharma reviews strategic options amid fiscal changes - Investing.com India
MEI Pharma confirms continuation of evaluation of strategic alternatives - TipRanks
MEI Pharma Reports Fiscal Year End 2024 Cash Position - The Bakersfield Californian
Expanding the Bispecific Antibody Market from CAR-Ts to Drive Follicular Lymphoma's Future | DelveInsight - PR Newswire UK
LPL Financial (NASDAQ:LPLA) Research Coverage Started at Wells Fargo & Company - Defense World
Los Angeles Capital Management LLC Reduces Stake in Martin Marietta Materials, Inc. (NYSE:MLM) - Defense World
Mei Pharma announces exclusive license agreement with Presage Biosciences for voruciclib - Reuters
Histone Deacetylase Inhibitors Report 2024, Industry Analysis And Overview By 2033 - WhaTech
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry - openPR
Helsinn Investment Fund reports 7.1 pct passive stake in MEI PharmaSEC filing - Reuters
MEIP (MEI Pharma) Dividends per Share : $0.00 (TTM As of Mar. 2024) - GuruFocus.com
Rx Rundown: Vantive, Gilead Sciences, Halda Therapeutics and more - MM+M Online
MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives - StockTitan
StockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
GreenWood Investors First Half 2024 Letter - Seeking Alpha
MEI Pharma (MEIP) – Research Analysts’ Recent Ratings Updates - Defense World
Game-Changing BCL-2 Inhibitors Set to Revolutionize Cancer Treatment Market | DelveInsight - GlobeNewswire
MEI Pharma announces executive departures and strategic shifts - Investing.com
MEI Pharma announces executive departures and strategic shifts By Investing.com - Investing.com Canada
MEI Pharma Explores Strategic Shifts, Leadership Changes - TipRanks
Mei Pharma Inc Stock (MEIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):